Note from the last announcement below - Rutherrin not as photosensitiser but as radiosensitiser. Truly non-invasive cancer therapy - that will be something for the markets.
‘In 2021, Theralase® plans to complete the non-Good Laboratory Practice (“GLP”) and GLP toxicology of Rutherrin® (TLD-1433 combined with transferrin) to be used as a radiosensitizer in the treatment of multiple solid tumor types: including Glio-Blastoma Muliforme (“GBM”) and Non-Small Cell Lung Cancer (“NSCLC”) among others.’